Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03236428 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
A Phase 2 study of Smoldering Multiple Myeloma and Monoclonal Gammopathy, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 6
- Study locations
NCT03236428 is a Phase 2 study of Smoldering Multiple Myeloma and Monoclonal Gammopathy that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 42 participants, below the 798-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT03236428, a Phase 2 study of Smoldering Multiple Myeloma and Monoclonal Gammopathy, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 6
- Study locations
Study Summary
This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is: -Daratumumab
Conditions Studied
Interventions
- DRUG Daratumumab
Study Locations (6)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
California
- Pacific Cancer Care - Monterey
Colorado
- Colorado Blood Cancer Institute - Denver
Michigan
- Karmanos Cancer Insitute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-11-24 |
| Est. Completion | 2026-10-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03236428
The ClinicalTrials.gov registry entry for NCT03236428 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 798-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (95% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Smoldering Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Daratumumab is the first listed.
NCT03236428 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03236428 about?
NCT03236428 is a clinical study titled "Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma". This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is: -Daratumumab
What is the current status of trial NCT03236428?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2017-11-24. Estimated completion is 2026-10-04.
What conditions does trial NCT03236428 study?
This clinical trial studies the following conditions: Smoldering Multiple Myeloma, Monoclonal Gammopathy.
What interventions are being tested in trial NCT03236428?
The interventions under investigation include: Daratumumab (DRUG).
Who is sponsoring clinical trial NCT03236428?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03236428 being conducted?
This trial has 6 study locations across California, Colorado, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
RECRUITING · Phase 2
-
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 2
-
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
ACTIVE NOT RECRUITING · Phase 2
-
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
ACTIVE NOT RECRUITING · Phase 2
-
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.